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Abstract: Viedma ripening is an emerging method for the
solid-phase deracemization of mixtures of enantiomers. Up to
now, the scope of the method has remained limited to
molecules with a single stereocenter. We show here that this
method can be extended to obtain a single enantiomer from
a mixture of stereoisomers with two different stereocenters. In
addition, we show that by using tailor-made chiral additives,
the conversion time can be reduced by a factor of 100.
Among the 45 drugs that were approved by the FDA (Food
and Drug Administration) in 2015, thirteen were achiral,
three contained a single stereocenter, sixteen were small
molecules containing multiple stereocenters, and thirteen
were large biomolecules.[1] Due to the different bioactivity of
the enantiomers, all of them (with the exception of the achiral
drugs) are marketed as a single enantiomer. This clearly
shows that obtaining molecules in enantiomerically pure form
is of vital importance to human healthcare.[2] When synthesis
yields a combination of enantiomers, diastereomeric salt
formation is a frequently used method to separate the desired
enantiomer from its unwanted mirror image isomer.[3] This
implies, however, that half of the product is discarded.
Alternatively, deracemization methods can be used, in
which the unwanted enantiomer is converted into the desired
product. One such deracemization method is Viedma ripen-
ing.[4] This process involves the solid-phase deracemization of
a vigorously ground suspension of crystals, enabled by
simultaneous solution-phase racemization.[5] A key require-
ment for the process is that the two enantiomers crystallize in
separate crystals, that is, as a racemic conglomerate. Over the
past few years, various types of molecules have been
deracemized using this approach.[6]
Up to now, only molecules with a single stereocenter have
been deracemized using Viedma ripening. However, as
mentioned, the majority of drug molecules are enantiopure
and contain multiple stereocenters. Conversion of such
compounds into a single enantiomer using such grinding
experiments is obviously more challenging. This is due to the
process involving 2n chiral compounds (with n the number of
stereocenters), instead of only two. Of these 2n compounds,
one set of enantiomers will be the thermodynamically most
favorable one, whereas the other diastereomers will have
a higher energy (or higher solubility). Sakamoto et al. used
this difference in stability for a related experiment.[7] They
studied a system with two stereocenters, of which one was
enantiopure and could not epimerize, while the second one
could epimerize in solution, resulting in a solid-phase that
contained only a single diastereomer. Other crystallization
methods that lead to the formation of a single enantiomer
exist as well.[8] In the case of Viedma ripening, it is important
that the thermodynamically more stable set of enantiomers
crystallizes as a racemic conglomerate (Figure 1).
The crystallization behavior of the less stable diastereo-
mers is expected to be less important, since these compounds
will eventually be eliminated from the solid phase. More
challenging is the interconversion (racemization) of the two
enantiomers, since this requires epimerization of all chiral
centers. This can be achieved if the centers epimerize in
a (near) identical way, or if the conditions for the different
epimerization pathways are compatible. As a first step
towards multiple stereocenters, we herewith show a successful
demonstration on two molecules with two different stereo-
centers to which these conditions apply. From a total of four
diastereomers, a single one was obtained using grinding
experiments. To the best of our knowledge, this is the first
example of conversion of a stereoisomeric mixture of a com-
pound with multiple stereocenters into only one enantiomer
using such grinding experiments. So far, experiments by
Hachiya et al. approximate this goal most closely, but using
total spontaneous resolution instead.[9] They succeeded in
partially converting molecules with two identical stereocen-
ters (meaning their system consisted of only three stereoiso-
Figure 1. In order to successfully convert a compound with two
stereocenters into a single stereoisomer using grinding experiments,
epimerization of both stereocenters, as well as crystallization of the
most stable pair of enantiomers as a racemic conglomerate, is
required.
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mers (one pair of enantiomers (1) and the corresponding
achiral meso compound) instead of four stereoisomers (two
pairs of enantiomers), Figure 2).
Compounds 2 and 3 are examples of molecules with two
different stereocenters, which thus exhibit four distinguish-
able stereoisomers. They belong to the class of succinimides,
some of which exhibit anticonvulsant properties. They are
structurally closely related to phensuximide (imide 4), a drug
used to treat epilepsy.[10]Related methylated succinimides are
known for their antifungal activity, of which the enantiopure
(R,R)-configured succinimides are the most effective ones.[11]
Obtaining such succinimides in enantiopure form is therefore
highly relevant.
In case of compounds 2 and 3, the trans diastereomers
(3R,4R and 3S,4S) crystallize as a racemic conglomerate. For
compound 2, the cis isomers (3R,4S and 3S,4R) form a rare
example of a solid solution.[12] It is envisioned that the trans
diastereomers are more stable, since this configuration is less
sterically hindered. NMR experiments confirmed this hypoth-
esis.
Epimerization of both stereocenters can be achieved by
adding DBU (1,8-diazabicyclo-[5.4.0]undec-7-ene) as a base.
When exposing a solution of compound 2 to epimerization
conditions, only 2% was present as the cis isomer at room
temperature as observed in the 1H NMR spectrum. This
corresponds to the conglomerate trans form beingmore stable
by 2.5 kcalmol@1 (in solution), thus making this system
potentially suitable for Viedma ripening (Figure 3).
Since the synthesis of compound 2 solely yielded the cis
diastereomer (through hydrogenation of the corresponding
maleimide derivative), this isomer was used as the starting
point for the grinding experiments. Upon addition of the
racemization catalyst (DBU), the dissolved cis diastereomers
were epimerized into the trans form. Further dissolution and
subsequent epimerization of cis-2 resulted in supersaturation
and consequent crystallization of trans-2. This process hap-
pened relatively fast in a time span of several minutes
(Figure 4).
Using temperature-dependent selective exchange spec-
troscopy measurements, it was found that the transition-state
barrier for the conversion of cis to trans was only DG=
17.0 kcalmol@1. This results in a half-life of approximately
one second (using the Eyring equation). The limiting factor in
this process is thus the dissolution, rather than the epimeriza-
tion of the cis compound. Next, Viedma ripening conditions
resulted in deracemization of the crystals to provide only one
of the two trans enantiomers. Racemization of one trans
isomer into the enantiomeric trans isomer happens at one
center at a time, through sequential epimerization of the two
chiral centers. The cis isomer is thus an intermediate in the
racemization pathway (Figure 3). The racemization barrier of
this process was calculated to be 19.5 kcalmol@1 (see the
Supporting Information). The deracemization process took
several days, showing the exponential behavior typical for
Viedma ripening. The long deracemization time is largely
caused by the long “dead time” before symmetry breaking
occurs. Deracemization proceeds stochastically, meaning that
different enantiomers are obtained as the crystalline product
in different experiments. In similar grinding experiments, the
production of a single enantiomer could also be achieved for
Figure 2. Deracemization of compounds of type 1 was previously
studied by Hachiya et al.[12] This study reports the conversion of
compounds 2 and 3 into single enantiomers, both of which are
structurally closely related to the anticonvulsant drug phensuximide
(4). Figure 3. Epimerization and racemization of compound 2 takes place
via reversible deprotonation of the stereocenters using DBU as
a catalyst. In this case, the two epimerization rates are nearly identical.
The indicated Gibbs free energies were determined using temperature-
dependent selective exchange spectroscopy.
Figure 4. Example of a grinding experiment on a suspension of
compound 2 starting from the cis diastereomers (quantities given are
those of the solid state). During the first 10 minutes of the experiment,
racemization was deliberately slowed down (by adding only a small
fraction of the final amount of DBU) to show the conversion of the cis
into the trans diastereomers (notice the two different time scales on
the x-axis). Note: the outcome of these experiments is stochastic,
meaning that upon repeating the experiment, both enantiomers are
equally likely to be obtained.
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a mixture of diastereoisomers of imide 3 (see Figure S3 in the
Supporting Information).
Since it is synthetically more useful to be able to direct the
outcome of a Viedma ripening experiment towards the
desired enantiomer, we explored the possibility of using
chiral additives, a strategy that was previously successfully
applied to achieve this goal (alternatively, a small amount of
enantiopure product might be added to achieve this same
goal).[13] A suitable chiral additive with high affinity for only
one of the two crystal forms may act as a selective growth
inhibitor.[14] In practice, molecules that closely resemble one
of the two enantiomers are selected for this purpose.
Importantly, the chiral additive should not alter its stereo-
chemical configuration during the experiment.
In this study, a combination of four enantiopure chiral
additives was synthesized,[15] all of which closely resemble the
same enantiomer of compound 2 (Figure 5). All additives
contain three chiral centers, of which one (carrying the
hydroxy group) cannot epimerize under the influence of
DBU. The locked chirality of this stereocenter also ensures
the desired chirality of the other two centers (since epime-
rization of these centers would result in sterically unfavored
cis orientations; see Supporting Information). Using these
tailor-made additives, the outcome of the grinding experi-
ments always proceeded in the desired direction. The
combination of the four additives based on (R,R)-2 always
resulted in (S,S)-2 as the product, while (S,S)-based additives
resulted in (R,R)-2. This phenomenon of opposing chirality
has been extensively studied and is known as the Lahav rule
of reversal.[13b,16] Since a combination of four additives was
used in all experiments,[17] we could not determine which of
the four was most effective. The deracemization curve shows
linear behavior, which is typical for the use of chiral
additives.[18] Not only could the desired enantiomer be
obtained using this approach, but the time required for
deracemization was also significantly reduced (Figure 6).
When starting from the racemic trans diastereomers, the
deracemization time was reduced from 70 to 2.5 hours. When
starting from cis-2, the conversion time was even reduced to
less than one hour, in other words a reduction of almost
a factor 100 was achieved.
This increased conversion speed is induced in the initial
phase of the process. Fast epimerization of the cis diastereo-
mer results in a supersaturated solution of the trans enantio-
mers. Since the rate of cis-to-trans epimerization is higher
than that of racemization, this results in crystallization of both
trans enantiomers in the absence of an additive. In the
presence of the additive, however, crystallization of the
enantiomer similar to the additive is hampered, thereby
resulting in preferential crystallization of the other enantio-
mer.[19] This results in a solid phase that already has a high
starting ee (around 25% after adding the racemization
catalyst) when the Viedma ripening commences. The time
required to obtain a single enantiomer is therefore even
shorter than with the use of an additive starting from trans-2.
In conclusion, we have shown that the formation of one
single isomer out of four stereoisomers using isomerization
and subsequent Viedma ripening is possible. The require-
ments are similar to those for compounds with only a single
stereocenter but can in practice be difficult. The desired pair
of enantiomers should be the thermodynamically most stable
pair and should also crystallize as a racemic conglomerate.
However, when the most stable pair of enantiomers crystal-
lizes as a racemic compound, derivatization[20] or salt for-
mation[21] can additionally be used to convert it into a con-
glomerate. Racemization can be more challenging, since
epimerization of all chiral centers should proceed under the
same conditions. These principles hold not only for a molecule
with two stereocenters, but also for more stereocenters. As
long as these requirements are met, Viedma ripening may be
used for the deracemization of any compound with multiple
stereocenters.
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Figure 5. Additives for directing the outcome of the Viedma ripening
experiments on compound 2. In all cases, all four (in this case (R,R)-
based) additives were used together.
Figure 6. Curves showing the conversion of compound 2 into a single
enantiomer, using 5 mol% of the chiral additives 5a–d (ee stands for
enantiomeric excess; +100% ee implies only RR while @100% ee
means only SS). Experiments were started from either the racemic
trans-(R,R/S,S) or cis-(R,S/S,R) diastereomers. Within a minute after
adding the racemization catalyst, all experiments contained only the
trans diastereomer. When additives were used, 5a–d were always used
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